Literature DB >> 19399923

Measurement of serum paraoxonase-1 activity in the evaluation of liver function.

Jordi Camps, Judit Marsillach, Jorge Joven.   

Abstract

Paraoxonase-1 (PON1) is an esterase and lactonase synthesized by the liver and found in the circulation associated with high-density lipoproteins. The physiological function of PON1 seems to be to degrade specific oxidized cholesteryl esters and oxidized phospholipids in lipoproteins and cell membranes. PON1 is, therefore, an antioxidant enzyme. Alterations in circulating PON1 levels have been reported in a variety of diseases involving oxidative stress including chronic liver diseases. Measurement of serum PON1 activity has been proposed as a potential test for the evaluation of liver function. However, this measurement is still restricted to research and has not been extensively applied in routine clinical chemistry laboratories. The reason for this restriction is due to the problem that the substrate commonly used for PON1 measurement, paraoxon, is toxic and unstable. The recent development of new assays with non-toxic substrates makes this proposal closer to a practical development. The present editorial summarizes PON1 biochemistry and function, its involvement with chronic liver impairment, and some aspects related to the measurement of PON1 activity in circulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399923      PMCID: PMC2675081          DOI: 10.3748/wjg.15.1929

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

1.  Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role.

Authors:  L Rodrigo; A F Hernández; J J López-Caballero; F Gil; A Pla
Journal:  Chem Biol Interact       Date:  2001-08-31       Impact factor: 5.192

2.  Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis.

Authors:  N Ferré; J Camps; M Cabré; A Paul; J Joven
Journal:  Metabolism       Date:  2001-09       Impact factor: 8.694

Review 3.  Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction.

Authors:  J A Solís Herruzo; I García Ruiz; M Pérez Carreras; M T Muñoz Yagüe
Journal:  Rev Esp Enferm Dig       Date:  2006-11       Impact factor: 2.086

4.  Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage.

Authors:  Natàlia Ferré; Jordi Camps; Eduard Prats; Elisabet Vilella; Antoni Paul; Lídia Figuera; Jorge Joven
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

5.  Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein.

Authors:  C J Ng; D J Wadleigh; A Gangopadhyay; S Hama; V R Grijalva; M Navab; A M Fogelman; S T Reddy
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

6.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

Authors:  S Billecke; D Draganov; R Counsell; P Stetson; C Watson; C Hsu; B N La Du
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

7.  Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans.

Authors:  Manjunath N Rao; Philippe Marmillot; Maoka Gong; David A Palmer; Leonard B Seeff; Doris B Strader; M Raj Lakshman
Journal:  Metabolism       Date:  2003-10       Impact factor: 8.694

8.  Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C.

Authors:  Sabina Mahmood; Miwa Kawanaka; Ayumi Kamei; Akiyoshi Izumi; Keiichi Nakata; Gouichi Niiyama; Hideji Ikeda; Shinichi Hanano; Mitsuhiko Suehiro; Kazumi Togawa; Gotaro Yamada
Journal:  Antioxid Redox Signal       Date:  2004-02       Impact factor: 8.401

9.  Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production.

Authors:  Meihui Pan; Arthur I Cederbaum; Yuan-Li Zhang; Henry N Ginsberg; Kevin Jon Williams; Edward A Fisher
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 10.  Lymphocyte-mediated liver injury in alcohol-related hepatitis.

Authors:  Robert G Batey; Qi Cao; Belinda Gould
Journal:  Alcohol       Date:  2002-05       Impact factor: 2.405

View more
  16 in total

Review 1.  Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors.

Authors:  Jordi Camps; Jorge Joven
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

2.  Hypercholesterolaemia, signs of islet microangiopathy and altered angiogenesis precede onset of type 2 diabetes in the Goto-Kakizaki (GK) rat.

Authors:  M-H Giroix; J-C Irminger; G Lacraz; C Noll; S Calderari; J A Ehses; J Coulaud; M Cornut; N Kassis; F Schmidlin; J-L Paul; M Kergoat; N Janel; P A Halban; F Homo-Delarche
Journal:  Diabetologia       Date:  2011-07-10       Impact factor: 10.122

3.  Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.

Authors:  Eline H van den Berg; Eke G Gruppen; Richard W James; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2018-11-19       Impact factor: 5.922

4.  Serum Basal Paraoxonase 1 Activity as an Additional Liver Function Test for the Evaluation of Patients with Chronic Hepatitis.

Authors:  Anand K Pyati; Chandrakanth K Halappa; Sudharani A Pyati; Vinod Wali
Journal:  J Clin Diagn Res       Date:  2015-11-01

5.  Current challenges and controversies in drug-induced liver injury.

Authors:  Alberto Corsini; Patricia Ganey; Cynthia Ju; Neil Kaplowitz; Dominique Pessayre; Robert Roth; Paul B Watkins; Mudher Albassam; Baolian Liu; Saray Stancic; Laura Suter; Michele Bortolini
Journal:  Drug Saf       Date:  2012-12-01       Impact factor: 5.606

6.  Salt overload in fructose-fed insulin-resistant rats decreases paraoxonase-1 activity.

Authors:  Waleska Cláudia Dornas; Wanderson Geraldo de Lima; Rinaldo Cardoso Dos Santos; Melina Oliveira de Souza; Maísa Silva; Mirla Fiuza Diniz; Marcelo Eustáquio Silva
Journal:  Nutr Metab (Lond)       Date:  2012-06-27       Impact factor: 4.169

7.  Paraoxonase 1 Phenotype and Mass in South Asian versus Caucasian Renal Transplant Recipients.

Authors:  Philip W Connelly; Graham F Maguire; Michelle M Nash; Lindita Rapi; Andrew T Yan; G V Ramesh Prasad
Journal:  J Lipids       Date:  2012-06-03

8.  Effect of taurine supplementation on hyperhomocysteinemia and markers of oxidative stress in high fructose diet induced insulin resistance.

Authors:  Hala O El Mesallamy; Ebtehal El-Demerdash; Lamiaa N Hammad; Hekmat M El Magdoub
Journal:  Diabetol Metab Syndr       Date:  2010-06-30       Impact factor: 3.320

9.  Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis.

Authors:  Stephan Riedmaier; Kathrin Klein; Stefan Winter; Ute Hofmann; Matthias Schwab; Ulrich M Zanger
Journal:  Front Pharmacol       Date:  2011-07-27       Impact factor: 5.810

10.  Serum paraoxonase-1 as biomarker for improved diagnosis of fatty liver in dairy cows.

Authors:  Ayman Samir Farid; Kazuyuki Honkawa; Eman Mohamed Fath; Nariaki Nonaka; Yoichiro Horii
Journal:  BMC Vet Res       Date:  2013-04-11       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.